As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

AND THIS COULD BE A STEP FORWARD FOR ENDOMETRIOSIS PATIENTS. ASHLEY. THAT’S RIGHT. THE JOHNS HOPKINS TEAM DEVELOPED DELIVERS MRNA TO THE INNER LINING OF THE UTERUS. DOING SO ACTUALLY IMPROVES EMBRYO ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

There's a potential new method to treat infertility through mRNA technology, according to Johns Hopkins Medicine research. In what could be a step forward for endometriosis patients, the method that ...

Moderna shares surge 16% to $50 on five-year melanoma vaccine data showing 49% risk reduction. Analysts target $29.93 despite ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...